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A B S T R A C TOutcomes research literature has many examples of high-quality,
reliable patient-reported outcome (PRO) data entered directly by elec-
tronic means, ePRO, compared to data entered from original results on
paper. Clinical trial managers are increasingly using ePRO data collec-
tion for PRO-based end points. Regulatory review dictates the rules to
follow with ePRO data collection for medical label claims. A critical
component for regulatory compliance is evidence of the validation of
these electronic data collection systems. Validation of electronic sys-
tems is a process versus a focused activity that ﬁnishes at a single point
in time. Eight steps need to be described and undertaken to qualify the
validation of the data collection software in its target environment:
requirements deﬁnition, design, coding, testing, tracing, user acceptance
testing, installation and conﬁguration, and decommissioning. These
elements are consistent with recent regulatory guidance for systems
validation. This report was written to explain how the validation
process works for sponsors, trial teams, and other users of electronicthe Task Force
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ndence to: Elizabeth Molsen, Director, Scientiﬁc &data collection devices responsible for verifying the quality of the data
entered into relational databases from such devices. It is a guide on the
requirements and documentation needed from a data collection sys-
tems provider to demonstrate systems validation. It is a practical source
of information for study teams to ensure that ePRO providers are using
system validation and implementation processes that will ensure the
systems and services: operate reliably when in practical use; produce
accurate and complete data and data ﬁles; support management control
and comply with any existing regulations. Furthermore, this short
report will increase user understanding of the requirements for a
technology review leading to more informed and balanced recommen-
dations or decisions on electronic data collection methods.
Keywords: electronic data collection, ePRO, PRO, systems validation.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Meeting in Baltimore. ISPOR members contributed to this
consensus report by submitting written comments during the
review process and oral comments during the forum presenta-
tion. The authors revised the report several more times and
sent the ﬁnal draft once again to the ISPOR PRO Review Group,
as well as announced an invitation to review to the full ISPOR
membership.
All comments, many of which were substantive and con-
structive, were considered and addressed as appropriate by the
task force authorship team. Further adjustments were made per
the feedback gained and once consensus was reached by all
authors, the ﬁnal report was submitted to Value in Health.
Written comments and a list of reviewers are published at
the ISPOR Web site on the task force’s Web page: http://www.
ispor.org/sigs/ePROsystemvalidationsg.asp. The task force report
and Web page may also be accessed via the ISPOR homepage
(www.ispor.org) via the purple Research Tools menu, Good
Practices for Outcomes Research.
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The patient’s experience has become increasingly important in
evaluations of the effectiveness and safety of medical products,
particularly drugs and devices. It complements the use of
clinician evaluations, objective statistics, such as survival rates,
and other traditional indicators of clinical efﬁcacy and safety.
Clinical researchers routinely incorporate patient-reported out-
come (PRO) assessments in clinical trials to help measure the
effect of a medical product on concepts such as symptom
severity and physical or mental function. PRO assessments can
be a primary or a secondary end point in determining treatment
efﬁcacy. In some cases, such as fatigue or pain assessment, a PRO
may be the only feasible end point because there are no markers
of disease or treatment activity measurable by a clinician,
observer, or laboratory [1].
According to the US FDA, a PRO is “any report of the status of a
patient’s health condition that comes directly from the patient
without interpretation of the patient’s response by a clinician or
anyone else” [2]. It can be measured in absolute terms (e.g.,
severity of a sign, symptom, or state of a disease) or as a change
from a previous measure [2]. The European Medicines Agency’s
(EMA’s) Reﬂection Paper on the Regulatory Guidance for the Use
of Health Related Quality Of Life (HRQL) Measures in the Evalua-
tion of Medicinal Products deﬁnes a PRO similarly as “any
outcome directly evaluated by the patient and based on patient’s
perception of a disease and its treatment(s)” [3]. More simply,
PROs are the effects of the disease and/or its treatment reported
by the patient [1].
In a clinical trial, after subject safety, a primary concern of
regulators is data quality and integrity [4]. From the clinical trial
sponsor’s perspective, the integrity and quality of data are critical
for trial credibility as well as compliance with FDA, EMA, and
other governing bodies. FDA's acceptance of data from clinical
trials for regulatory decision-making purposes depends on its
ability to verify the quality and integrity of the data during FDA
onsite inspections and audits [5].
Clinical trial managers are increasingly using ePRO, electronic
collection of PRO data directly from the patient for PRO-based
end points. ePRO leads to improved data quality, more complete
data, less subject and administrative burden, as well as better
implementation of skip patterns [1,6]. Electronic data collection
yields more reliable and accurate data, allowing a stronger test of
the study objectives and a better picture of the patient's experi-
ence [6]. Regulatory review dictates the rules to follow with
electronic data collection. Whether a trial manager uses an
electronic or paper-based questionnaire to collect data, the
fundamental issues affecting data accuracy, (e.g., traceability
and change control) are common to both electronic and paper
systems.
Evidence may be desired to demonstrate that subjects inter-
pret and respond to the PRO instrument’s items/questions the
same way regardless of the data collection mode [1,5]. Changing
the mode of data collection and the assessment of measurement
equivalence between modes are covered in a previous ISPOR PRO
task force report, “Recommendations on Evidence Needed to
Support Measurement Equivalence between Electronic and
Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR
ePRO Good Research Practices Task Force Report” [1].
Regardless of the mode of administration (self- vs. inter-
viewer-administered) or the method of electronic data collection
(the tool used for capturing the data, such as interactive voice
response systems, Web-based data entry, or ePRO devices),
systems validation must meet the standards of the FDA and
the EMA. This is done by validating the process used to develop,
support, and maintain the device and computerized system [5–7].
In simple terms, there must be proof that the process does whatit is supposed to do. For example, if a “5” is entered on the screen
through a handheld or desktop data entry device, the subject's
response must “map” correctly on the database—registering
correctly as a value of 5 in the database.
For ePRO, this is complicated by the fact that existing regu-
lations and guidelines were originally developed for paper ques-
tionnaires and diaries. At this time, there is no single
development or deployment method prescribed by either regu-
latory authorities or industry best practices. Because there is no
speciﬁc regulation or guidance from these agencies regarding exactly how
validation of ePRO systems should be performed, we infer the appro-
priate standards from their guidance on similar topics, such as
validation of systems used to manufacture medical devices. (See
Supplementary Materials for regulations relevant to clinical trials
and ePRO systems development & validation, found at http://dx.
doi.org/10.1016/j.jval.2013.04.002.)
With ePRO, there are two software delivery choices, each with
its own validation process. The ﬁrst is a traditional, custom
software method—developing one software system for each trial.
Portions of existing software code may be reused for this. The
entire system undergoes a rigorous set of validation activities
prior to deployment for trial use [8]. The second choice is a
vendor-created platform that is tailored and redeployed for each
trial. The platform undergoes a rigorous set of validation activ-
ities during the initial development. This method allows simply
validating the tailoring effort for each trial. Both delivery meth-
ods have value. One retains complete ﬂexibility at a greater
development time and cost, while the second features a faster
development time with the cost of limited ﬂexibility.
Because the techniques for validating the performance of
ePRO systems and the regulations impacting validation may not
be clear to all sponsoring project managers and trial team
members, the primary goal of this report is to assist in under-
standing the technical nature of ePRO systems and the ePRO
system validation process. With an ePRO system, validation is a
responsibility split between the provider of the ePRO system and
the sponsor that uses it. It is important to understand the nature
of these responsibilities and how they should be shared.
The secondary goal of this report is to make recommenda-
tions for sponsors and trial project managers on system valida-
tion—more speciﬁcally on the responsibilities of each
participating party. This report addresses the technical nature
of ePRO data collection systems and validation process. It will
provide the sponsor with insight into the requirements for a
technology review and a basis for comparison of different ePRO
system providers and their respective service offerings leading to
more informed and balanced recommendation(s) or decision(s)
on electronic data collection systems.
Furthermore, the report will provide an understanding of the
effort required by the sponsor to complement the validation
services proposed by the system provider. When an ePRO system
provider simply offers the device and data system, but does not
offer the required validation service, the burden of fulﬁlling that
responsibility falls on the sponsor. Note that throughout the
document, “sponsor” is used to refer to the clinical trial team
working with an ePRO provider. These recommendations would
apply equally to a contract research organization (CRO) or other
entity that is engaging an ePRO system provider for the creation of
an ePRO system to be used in medical product registration trials.
The general principles addressed in this report can be applied to
other research settings in which subjects use an electronic means
to enter data that represent an answer to a question.
Finally, the report includes relevant regulations due to the
critical nature of compliance in these processes and within the
clinical trial itself. Appendix 1 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2013.04.002 includes the interna-
tional standards for clinical trials and manufacturing and major
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ePRO systems development and validation for clinical trials.Basic Validation Principles
Deﬁnition
The original 1987 FDA Guideline on General Principles of Process
Validation deﬁned process validation as follows:
Establishing documented evidence that provides a high
degree of assurance that a speciﬁc process will consistently
produce a product meeting its predetermined speciﬁcations
and quality attributes. [9]
The 2011 Guidance for Industry Process Validation: General
Principles and Practices, while consistent with these basic prin-
ciples, has been updated for the 21st century. The current
deﬁnition is as follows:
The collection and evaluation of data, from the process design
stage through commercial production, which establishes sci-
entiﬁc evidence that a process is capable of consistently
delivering quality product. Process validation involves a series
of activities taking place over the life cycle of the product and
process. [10]
The systems validation process encompasses the full system
development life cycle from initiation to development, testing
and production, to the ﬁnal step, decommissioning. According to
the European Union’s Guide to Good Manufacturing Practice,
computerized systems guidance, validation documentation, and
reports should cover the pertinent steps of the life cycle. Manu-
facturers (in this case, ePRO providers) should be able to justify
their standards, protocols, acceptance criteria procedures, and
records on the basis of their risk assessment [11]. FDA’s guidance
is similar, recommending integration of software life cycle
management and risk management with software validation
and veriﬁcation activities conducted throughout the entire soft-
ware life cycle [12].
It is important to note that validation, by itself, does not stop
with software once it is production-ready or “on the shelf.”
Validation is not a terminal state at a point in time, but a status
maintained by a continuing conformance to a software life cycle
and quality management system [7,12]. To maintain the valida-
tion status, care must be taken to document any changes and
reexecute any relevant validation activities from when the
system is operational until it is retired and decommissioned.
Stepwise, it begins with the system requirements documen-
tation and proceeds through the following steps: requirements
deﬁnition, design, coding, testing, tracing, user acceptance test-
ing (UAT), installation and conﬁguration, and ﬁnally decommis-
sioning, to qualify the validation of the software in its target
environment. Any ePRO development effort should cover a
standard list of deliverables addressing the steps outlined below.
Essential Components of the Validation Process
The systems development life cycle is an outline of the activities,
tasks, responsibilities, and deliverables required to develop a
high-quality, validated electronic data collection system. The
systems development life cycle methodology used by the ePRO
provider should be scrutinized to determine whether it includes,
at a minimum, these critical elements:1. System requirements
2. System design
3. Coding/tailoring/software development4. Testing by system provider
5. Traceability
6. UAT
7. Installation/conﬁguration management
8. Decommissioning planSystem requirements
What it is. The purpose of systems requirements documenta-
tion is to describe all aspects of the system, regardless of the
technology used. The resulting documentation covers the needs
of the study protocol, target patient population, and clinical staff
and needs to be accepted formally before any system develop-
ment begins [13].
The system requirements documentation is the blueprint for
what the system will do. It enables 1) the clinical trial team to
request changes while the ePRO system is still on paper—when
changes are easy, quick, low risk, and inexpensive to make; 2) the
system provider’s team to get a clear and thorough description of
the system that it needs to design, develop, and deliver. For
example, the programmers, test strategy writers, and training
developers need a detailed picture of every aspect of the system
to fulﬁll each of their system validation responsibilities and to
ensure that their individual deliverables complement each other
properly, resulting in a high-quality system for the trial; and 3) the
same detailed expectations of the system to be understood by both
the team and the provider. This is especially important during
UAT (described later) and during the system’s use in the trial.
Other names for this documentation. It can also be called user
requirements, functional requirements, and user speciﬁcations, among
others. Documentation may be in one document or several.
Regardless, it is critical to both parties that there is documenta-
tion with a very clear, thorough description of all aspects of the
system [13,14].
Clinical trial team involvement. The team’s involvement is
critical during the requirements gathering and deﬁnition stage,
whether or not the ePRO system will be developed internally, or
whether it will be developed by an external provider.
Clinical trial teams who do not have the expertise to write the
systems requirements document will usually rely on the ePRO
system provider, a consultant, or technical experts inside their
organization for producing it. The clinical trial team provides the
clinical trial protocol to these experts. In most cases, the team
meets with the systems requirements document authors to
determine how the system should work to meet the protocol’s
requirements, as well as the needs of the users at clinic sites, the
target patient population, and the stakeholders in the sponsor’s
organization. Sponsor organization stakeholders include clinical
operations, data management, biostatistics, outcomes research
or health economics, and regulatory compliance [14].
Items discussed with the clinical team include screen ﬂow
(individual screen designs to properly display the PRO items),
data entry ﬁeld edits, data transfer requirements, data ﬁle
formats, security requirements, as well as compliance with FDA
regulation 21 CFR Part 11 [15] on electronic records, electronic
signatures, and a multitude of other details. The sponsor has to
translate regulatory directives into system functionality from
data access to reporting to retention for audit and inspection [6].
When a draft of the system requirements document is com-
plete, it is imperative that the clinical trial team provides thought-
ful review and feedback to request any necessary changes. These
sponsor-requested changes must be made according to an agreed-
upon timeline to support delivery dates. When the clinical trial
team and the ePRO system provider are both satisﬁed with the
system requirements document, in that it correctly and completely
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this documentation, providing evidence of their agreement and
approval. Key members of the system provider’s project team also
sign this documentation to provide evidence of their agreement
and commitment to deliver the system as described [13,14].
Why it is important. The system requirements documentation is
the basis for all subsequent system validation processes and
deliverables. If sections are vague, ambiguous, or missing, there will
be differences in interpretation and misunderstandings between the
clinical trial team and ePRO system provider team members. These
differences will then be discovered only later in the user acceptance
process, which can result in delays in patient enrollment, risk in the
quality and stability of the software, as well as functional issues and
deﬁciencies during the trial. Therefore, it is critical that the docu-
ment be precise, clear, correct, and complete [13,14,16].
Minimum content. The system requirements document should
include everything needed to provide a clear, detailed description
of the system. At a minimum, it should show and/or precisely
describe all aspects of the system affecting the user, including the
instruments selected, screen shots (personal digital assistant
[PDA], tablet, or Web), voice prompts (interactive voice response),
data entry ﬁelds, edit checks, error messages, navigation logic,
behavior of all buttons (PDA, tablet, or Web), algorithms, alarms,
timeouts, security functions, audit trails, electronic signatures,
alerts to subjects and site staff, and report designs. Text descrip-
tions of these items must be accompanied by graphics where
needed to ensure clarity.
Regardless of the technology to be used for the trial, ideal
system requirements documentation should include the follow-
ing topics: 1) purpose or objective; 2) deﬁnitions; 3) referenced
documents; 4) assumptions; 5) system and process ﬂows includ-
ing ﬂowcharts that show the screen ﬂows and related logic for the
entire system; and 6) functional requirements. The latter—the
heart of the document—may be lengthy, often organized by the
user group (e.g., systems requirements for clinic staff), but can be
organized in any manner that makes it easy to understand.
This short outline of the functional requirements in system
requirements documentation is a sample of content that would
be expected for the ﬁrst screen in a section describing a patient
screen ﬂow. Each item in the outline would be followed by a clear
and thorough description.
Functional Requirements
Section 1- Patient Screen Flow1. First Screen- Patient Login
a. Screen Shot
b. Data on Screen Banner
1) Date
2) Time
c. Data Entry Fields
1) Patient PIN number
a) Check for 4 character numeric and error message
b) Check for match with subject and error message
d.
Navigation buttons
1) Cancel button
a) Data not saved
b) System takes user to previous screen
2) OK button
a) Check for PIN number entered
b) System takes user to next screenImportant quality management processes to be aware Of.
The ﬁrst important step in developing high-quality systemrequirements is for all members from the system provider and
the study team to carefully read and study the trial protocol and
any other documents describing the trial and standards of the
sponsor. Key members from the system provider team should then
lead a collaborative, detailed, and thoughtful requirements-
gathering discussion to determine how the clinical trial team
would like the system to work to support its protocol, data quality
and integrity, clinical sites, and staff [13,14]. The individual facil-
itating the discussion needs to remind the participants that there
is always a trade-off between timeline, cost, and quality. The more
features that are incorporated into the system, the longer it will
take and the more costly it will be to build and validate the system.
The requirements-gathering discussion should be followed by
a ﬁrst draft of the system requirements section/document. This
ﬁrst draft should be read carefully by team members on both
sides. Another collaborative discussion should follow whereby
the clinical trial team provides feedback and requests changes
[6,13,14]. A requirements-gathering process typically requires at
least two revisions of the ﬁrst draft to produce ﬁnal system
requirements documentation. If the scope of the approved
system requirements exceeds the original assumptions made in
planning the project, a revision will be needed in the project plan,
which may affect the study timeline and budget. The system
provider should provide quality control on the production of the
system requirements documentation, such that an independent
party familiar with the system requirements reviews the ﬁnal
documentation before it is delivered to the clinical trial team.System design
What it is. The design phase involves development of system
design documentation providing a complete, clear, detailed,
technical description of how the ePRO system will be built to meet
the needs of the protocol and the users. The documentation
serves to communicate to the developer what has to be included
as well as what is out of scope of the system. The documentation
needs to cover both the context in which the system will operate
and the details necessary to free the developer from uncertainty
as to how it should be built [13,14].
The ePRO system provider is responsible for developing the bulk
of this documentation. The sponsor or CRO responsible for upload-
ing ePRO data to the study database, however, may need to provide
speciﬁcations for the data transfer ﬁles for the ePRO system provider
to use when building/conﬁguring the data transfer module.
Software development professionals use the system design
documentation to write the programs and/or set technical
parameter values for the ePRO system. Some ePRO systems use
a base system that is conﬁgured for use in a speciﬁc study using
parameters and settings, with minimal programming of source
code to complement the base system.
The initial concept of how to translate the requirements into a
viable system may undergo revision as the system is built and
subjected to unit tests. As the system is built, the author of the
system design documentation needs to communicate effectively
with the clinical team and the software development team to
ensure that the design to be implemented still meets the require-
ments of the users [17].
System design documentation needs to cover three principal
functions, which correspond directly to the following modules of
a typical ePRO system: Data collection and storage (collection of data by any of
several technologies to be stored on a server controlled by
the ePRO system provider) Web portal and alerts (allowing source data on the server to be
displayed, reports to be generated, and alerts to be triggered
and sent)
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for sending to the sponsor or its CRO).
Other names for this documentation. It is also known as the
software design speciﬁcation, technical design speciﬁcation, or
system speciﬁcation documentation.
Clinical trial team involvement. The role of the clinical trial
team is the review and acceptance of the system design doc-
umentation. This role should be clariﬁed early in the life of the
project to avoid unexpected delays in moving on to system
development. The clinical trial team should seek to clarify areas
where the system provider has not correctly interpreted a
requirement within the design documentation or has provided
an incomplete description of the solution. Where the documen-
tation is difﬁcult to interpret, the clinical trial team should seek
assistance from technical subject matter experts, rather than
assuming that the speciﬁcation covers the requirements correctly
and fully.
Why it is Important. The system design documentation is a
bridge between the system’s requirements and the software
developers. Getting this documentation right is a crucial step to
ensure that the software development effort will produce an
appropriate solution embraced by the system users and compli-
ant with clinical protocol [6,13,14].
Minimum content. The documentation should cover all
three of the modules described above, ideally with a separate
document or section for each one. Where a base system is
used and the speciﬁcations of the base system are not
changing, the ePRO system provider should make the relevant
portions of that documentation available to the clinical
trial team.
The data collection module’s system design documentation
needs to cover details not already in the system requirements
documentation on topics such as the following: the logic for handling screens, and
 the logic that controls the logon of the user and ﬂow of control
through the screens/scripts;
 edit checks that prevent entry of incorrect data or
commands;
 alerts to users; and
 other error handling logic.
In addition, the data collection module’s system design
documentation needs to cover details not already in the system
requirements documentation: 1) for technologies that require
sending data to a server, the logic and methods available for
data sending, including control processes for ensuring that data
sent are complete, accurate, and not duplicated, and 2) for all
types of technologies, the handling of partial/incomplete saving
of data to the server (e.g., rollback).
The Web portal module’s system design documentation needs
to cover design details not already in the system requirements
documentation on topics such as the following: log on and password security;
 security groups and their authority over data access;
 display of clinical data, including raw data, metadata, and
audit trails;
 display of and ﬂow between reports, both standard and
custom;
 alerts to users and the logic of their triggers; and
 other processes, such as automation of device logistics or data
change requests.The data transfer module’s system design documentation
needs to cover details not already in the system requirements
documentation on topics such as the following: timing, frequency, and method of data transfer;
 the set of data elements to be transferred and their format;
 the process for transforming data into the format speciﬁed by
the sponsor or its CRO; and
 control processes for ensuring that data transfers are com-
plete, accurate, and not duplicated.
Important quality management processes to be aware of. The
system provider should provide quality controls on the produc-
tion of the system design documentation, such that an inde-
pendent party familiar with the system requirements reviews
the documentation before it is delivered to the clinical
trial team.
Coding/tailoring/software development
What It Is. Coding/tailoring/software development is the process
of writing code in a software programming language or assem-
bling and customizing modules of code that have already been
developed to meet the needs of a speciﬁc trial.
Why it is important. These processes are the building blocks of
the computer system that will be used in the clinical trial. Proper
execution and process documentation will lead to systems that are
relatively easy to maintain and easy to audit by third parties. [12].
Clinical trial team involvement. There is no clinical team
involvement due to the highly technical nature of this process.
Typically, the clinical trial team communicates through a project
manager and/or analyst who ensures that the trial requirements
are properly translated into speciﬁcations for the developers.
Important quality management processes to be aware of. As
with any process, the goal is to identify any problems or defects
as early as possible and to ensure that they are resolved [11]. In
development, there should be a review of the created code that
may be executed by one or more technical peers who understand
the languages and standards for the development method used
(code review). Prior to introducing new work into the larger
structure of the trial design, the developer (or a peer) should test
the individual modules to ensure that they perform properly and
are meeting the design requirements, constraints, and assump-
tions (unit testing) [18].
The discovery of any defects arising from quality processes
during software development should be documented with infor-
mation about the conditions under which the defect occurred to
allow for reproduction. See Appendix 2, Process Quality Descrip-
tion, in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2013.04.002. The defects should have a clear status
(e.g., open/assigned/ﬁxed/closed) so that they can be corrected in
the system and veriﬁed by a second party before they are deemed
to be resolved. As a system is developed, it should be possible to
trace the code created or modules used back to the speciﬁc design
elements they are implemented to fulﬁll.
Testing by system provider
What It Is. Testing for all items described in the system require-
ments document is critical to ensure that a new system meets
every agreed-upon requirement. The test plan describes the
strategy for testing the system to ensure the environment and
approach emulates real-world conditions. It also contains a
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ments [7,13].
Clinical trial team involvement. The clinical trial team does not
participate in the testing process; it is the responsibility of the
system provider.
Why it is important. The programs required to provide systems
for clinical trials are many thousands of lines of complex
interrelated code. Even with highly experienced, highly commit-
ted programmers who comply with good quality coding proc-
esses, the complexity of most clinical trial systems almost
guarantees that early versions of the system will not function
in perfect compliance with the systems requirements document.
Every system must be thoroughly tested.
System testing is done by following a detailed test plan and
test cases. A carefully executed test plan ensures that the system
will work as intended throughout the clinical trial [7,13].
Minimum content. The most important sections of a quality test
plan are the test strategy and the test cases. Testing Strategy: This section is typically developed by testing
team leaders, and it should document the strategy for testing
the system in conditions that closely approximate the trial.
For example, if a trial with enrollment in 10 countries will last
12 months with a 2-week run-in period and a 9-month treat-
ment period, the testing strategy needs to describe how the
test environment will be created, how data will be collected
and veriﬁed during the testing phase to simulate these
conditions, and how to provide assurance and a high level
of conﬁdence that the system will perform reliably during the
trial. Furthermore, the testing strategy must document the
testing approach to indicate how all requirements in the
system’s requirements will be covered. Test Cases: Also known as test scripts, they are the basis of the
testing strategy. They help determine whether the system is
complying exactly with the speciﬁed requirements.
Each test case contains step-by-step instructions for a test
engineer to enter a set of predeﬁned data, as well as a detailed
description of the expected results. When executing each test
case, the test engineer will indicate clearly whether the actual
results equaled the expected results and thus whether the test
case resulted in a “pass” or “fail.” If there is a “fail,” the
engineer will document the deviation from the expected
results in detail in an issue report, so that the programmer
can determine the cause of failure, resolve it, and document
the resolution.
Important testing approaches to be aware of
Multiple testing approaches must be used. This will minimize the
risk of system malfunctions and data ﬁle issues when the system
is used in real-world conditions. The testing process must include
the following as applicable for each requirement: Positive Testing: A wide range of valid entries and selections are
made to ensure valid entries will be accepted by the system. Boundary Testing: Entries are made just within the boundary
values (e.g., age range) and just on the outside of boundary
values to ensure edit checks on a ﬁeld are correct. Negative Testing: Omissions and/or invalid entries and selec-
tions are made to ensure all error conditions are properly
handled. Load Testing: A large data set of predeﬁned, valid data is
entered and veriﬁed both on a local system and on remote
systems (e.g., data repositories/servers) where the data will betransmitted throughout the trial, through comparison
to predeﬁned expected data sets. The size of the data set
should be large enough to ensure that all related systems—
the local system, the remote systems, the telecommunica-
tions system, and so on—can all easily accommodate more
than the expected volume of data for the study, and still
produce accurate results. Load testing is vital to provide
evidence that the systems will function properly in a
clinical trial. Regression Testing: This is critical after a programmer resolves
one or more issues. The purpose of regression testing is to
ensure the code changes do not damage other parts of the
system that were previously working. Regression testing is
necessary because code changes can often have unintended
consequences on other areas of the software. In cases of
substantial code changes, the entire system must be retested
to ensure that a high-quality system is delivered. When code
changes are very minor, for example, to correct a misspelling,
or other small error, regression testing can be more limited.
The validation team must be very thoughtful about the level
of risk introduced with code changes, and use a regression
test strategy that will signiﬁcantly minimize the risk.
Important management processes to be aware of. Test strat-
egies, plans, and test cases should go through multiple manage-
ment quality reviews and iterations within a system provider’s
team. When test cases are executed, system issues or defects will
often be found, which must be carefully documented and tracked
by the system testers. Programmers will then create and docu-
ment a new version of the system that contains the changes
made to resolve the system defects and issues. A new test
strategy will then be created for each new version of the system.
This new test strategy should address the risk of software
changes on previously performing system functions. Based on
this risk assessment, the test strategy will indicate all the test
cases that will be reexecuted to ensure that all defects have been
resolved and to ensure that adequate regression testing is done
to fully address the risk of the software changes and ensure a
reliably working system for the trial [7,13].
If there have been carefully executed quality processes by the
management of the system provider, only two to three iterations
of the test strategy and test case execution should be needed. The
conclusion is a successful User Acceptance Test by the study
team, and systems that work as intended during the clinical trial.
Traceability
What it is. Traceability plays a quality control role by establish-
ing that the software provided meets the user’s needs. It ensures
that all elements in the systems requirements document are
properly “traced” through to other critical systems validation
processes and documents.
A traceability matrix demonstrates that each requirement in
the systems requirements document has been accounted for in
the design document as well as in the test cases or scripts. It can
be used to track 1) the design (user) requirements for function of
the system; 2) the software (functional) requirements that are
speciﬁed to meet the user‘s requirements; and 3) the test cases
that are used to verify that the end product meets the software
and user requirements.
Testing matrices can take many forms. For example, tracing
can be accomplished from a unit test to the design requirements,
such as a developer testing a piece of code to see whether it
works in isolation. Another example is tracing from the test case
(formal testing of a speciﬁc software speciﬁcation) to the software
requirement.
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system requirement has been designed and coded in the software
and included in the software test cases. The traceability matrix
also ensures that all requirements are exercised by test cases
during system and user testing [13,14,17]. Keeping this tracing clear
along the way will support both the internal assessment that all design
elements have been appropriately tested and analysis later on if an
inspector is verifying validation through testing records of critical design
functions.
Most often there is not a single correlation between design
requirements, software requirements, and test cases. For exam-
ple, a single design requirement may require several functional
requirements to encompass the design feature; a single func-
tional requirement may require several test cases to verify that it
is working properly. Therefore, the traceability matrix documents
these dependencies between the functional user requirements
and the more technical software requirements.
Minimum content. A matrix that traces each systems require-
ment to a design element and to a test case is the minimum. The
matrix can be a stand-alone document or summarized in an
approved test report showing how the test cases checked for all
design requirements.
Clinical trial team involvement. None. Traceability is the
responsibility of the system provider. A sponsor may verify and
conﬁrm this effort as part of an audit.
Important quality management processes to be aware of. A
thorough traceability matrix prepared at this step can help
prevent oversights in the design that will be more difﬁcult and
expensive to manage or ﬁx later in the software development life
cycle. Like all processes and systems subject to quality control,
the traceability matrix should be examined by a system provider
employee independent of the development team.
User acceptance testing
What it is. UAT is the process by which the clinical trial team
determines whether the system meets expectations and per-
forms according to the system requirements documentation. If
there is an inconsistency between the clinical trial team’s expect-
ations and the system provided, it will arise at this point. UAT
should not commence until the system provider provides written
conﬁrmation that they it has completed its role in the validation
of the system. It should be noted that UAT is not a complete
revalidation effort conducted by the sponsoring clinical trial
team. Rather, it is a focused, risk-based approach to testing that
allows the clinical trial team to determine whether the system
complies with the key system requirements (which ultimately
reﬂect the protocol).
Other names for this documentation. UAT is also known as user
site testing.
Clinical trial team involvement. The clinical trial team must be
heavily involved in developing the testing strategy for the UAT
effort. It cannot be left solely to the system provider or a third
party. Those who wrote the protocol and provided requirements to
the system provider at the start of the project should contribute
toward verifying that these requirements have been covered [6].
Typically, the clinical trial team has several members
involved in executing the test scripts. The clinical trial team
plays a critical role in deciding whether the system is ready to go
live by reviewing the discrepancies found in UAT and how the
discrepancies are resolved (either by ﬁxing them or agreeing thatthe discrepancies do not require ﬁxes). Once the clinical trial
team has determined that the system is ready for production,
they should prepare and sign a formal document that accepts the
system as validated for its intended purposes [6,7].
It should be noted that UAT is distinctly different from usability
testing. In the 2009 ISPOR ePRO Task Force Report [1], usability
testing was deﬁned as examining “whether respondents from the
target population are able to use the software and the device
appropriately. This process includes formal documentation of
respondents' ability to navigate the electronic platform, follow
instructions, and answer questions” [p. 424]. More simply, can
subjects complete the computerized assessment as intended?
Usability testing involves subjects representative of the clin-
ical trial population. For example, children should be included in
the usability testing of an ePRO system for a pediatrics trial that
incorporates child self-report. UAT does not involve target pop-
ulation subjects; it is conducted between the trial team and the
ePRO provider. While both UAT and usability testing are neces-
sary and important to the overall success of the trial, UAT is
critical to determine whether the software complies with the user
requirements documents and written speciﬁcations.
Why it is important. UAT is an important step to verify that the
system has been built according to the original systems require-
ments document. A thorough UAT effort also provides the
clinical trial team with the opportunity to see how the system
is going to function as well as educate itself on the details
necessary to answer questions from study sites and auditors
once the system is in production. Furthermore, it helps build the
clinical trial team’s conﬁdence that the system will function well
throughout the trial.
Once completed, a successful UAT will answer three funda-
mental questions:1. Was the system designed and built according to the original
requirements?2. Did the original requirements fully cover what the clinical trial
team envisioned?3. Did we build the right diary for subjects to use in this trial?
[17].
While it may be tempting for the clinical trial team to rely on
the system provider’s validation efforts and skip UAT, this would
be inconsistent with The International Conference on Harmoni-
sation of Technical Requirements for Registration of Pharma-
ceuticals for Human Use Good Clinical Practice [19] that requires
the sponsor to take full responsibility for the quality and integrity
of trial data. The sponsor is responsible for implementing and
maintaining quality assurance and quality control systems with
written standard operating procedures (SOPs) to ensure that trials
are conducted and data are generated, documented (recorded),
and reported in compliance with the protocol, good clinical
practice (GCP), and the applicable regulatory requirement(s) [19].
Saving a few weeks in development time is a small price to pay for
avoiding negative regulatory inspection ﬁndings downstream.
Minimum content. To properly perform a UAT, the clinical trial
team documents a testing strategy in a UAT test plan [20]. This
strategy will guide the development of test scripts, assignment of
the appropriate set of testers, and deﬁne the test period (includ-
ing repeat testing as needed). While this is similar to the system
provider’s internal validation testing strategy, it is not as
extensive.
This plan should mention areas of testing that require
extensive testing and those that require little testing, based on
perception of risk [12]. For example, a requirement that the
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diary, where that score is used to determine whether a subject is
randomized into the study, would be of high importance; such a
requirement would require test cases sufﬁcient to cover random-
ization success and failure. A requirement that the alarm on the
device sounds reliably at 5:00 p.m. should require only cursory
testing during UAT, because alarms are typically a standard
feature of the base software.
Important quality management processes to be aware of. UAT
reliability can be improved by the use of a traceability matrix to
map the UAT test cases to the original requirements. The matrix
provides an efﬁcient method to determine whether all the key
requirements are covered by the UAT effort. In addition, inde-
pendent quality control of the test scripts is important to
minimize the risk of using scripts that cannot be executed as
designed or will not achieve their speciﬁc test objectives [13].
UAT sometimes results in the clinical trial team realizing that
the system is functioning as documented and designed, but it is
not fulﬁlling its undocumented expectations or requirements
implicit in the protocol. If the clinical trial team feels strongly
enough about making changes to how the system currently
functions, then the team is required to initiate a “change in
scope” process. Requirements are redocumented, and the entire
life cycle process is followed until another UAT effort is com-
pleted. It should be noted that only if there is time, a budget, and
a truly important issue, should the clinical trial team consider
revising requirements at this late stage, as the ﬁrst subject/ﬁrst
visit date could be impacted by these changes.
Quality cannot be built into a system by testing. UAT serves as
a control gate. If the system provider’s process of documenting
requirements, designing the system, or building it according to
design documentation is broken, then a feedback loop between
the sponsor and the system provider is needed to force improve-
ments in the upstream processes that led to the quality issues in
the ﬁrst place. Such a feedback loop can be implemented by
holding “Lessons Learned” meetings and requiring a sponsor and
system provider management to address the negative ﬁndings
from such meetings before the next project begins.
A process needs to be established to require formal documen-
tation of the lessons learned and the steps actually taken to
address them. Such an approach will help the system provider to
make substantial improvements in its validation processes,
which should lead to a smoother UAT effort in future projects.
Finally, UAT of the ePRO system does not complete the system
validation process. Until the ePRO system is installed in a
production end-user environment, the process is not considered
ﬁnal [7,8,13].
Installation/conﬁguration management
What It Is. Installation/conﬁguration management is the proc-
ess for the system provider to install the fully tested software,
using the methods described above, onto the ePRO device. It
includes localizing it for the intended user, providing a user
instruction manual, and describing planned system mainte-
nance. It also includes the base and study-speciﬁc server setup.
To ensure that the correct study version is deployed to the right
location, a robust conﬁguration/release management process is
required. This is true for both the study-speciﬁc server and client
components. Once installed on the target environments, the
system can be considered in a state of validation [7].
Why it is important. Because many clinical trials are global,
ePRO deployment with the correct software version and local
settings can be complex. The conﬁguration process is importantto ensure that the “ﬁnal,” “as-tested” version(s) of a system and
settings are deployed correctly (e.g., the Punjabi version with
correct language(s) and time zone is in Punjab, India). It is also
important to make sure that physical accessories, such as power
sources, are appropriate for the trial site and that training or user
materials are in the appropriate language(s).
Clinical trial team involvement. The clinical team should be
cognizant of the ePRO provider’s processes for conﬁguration
management, deployment, and logistics of shipping to multiple
global sites. Clinical team input is needed to ensure that the
correct localized product is shipped to the site.
Important quality management processes to be aware of. The
ePRO provider’s installation and conﬁguration team should be
using a carefully developed quality-controlled checklist to man-
age the software installation on each ePRO solution. The checklist
provides documentation for the settings on each device and
internal quality reviews of the settings and accountability of
the installation and conﬁguration staff.
Finally, a statistical quality control sampling of subject
devices is recommended to ensure that the devices and acces-
sories designed for a region are correct. The end result is to
ensure that the clinical team has deployed an ePRO system to
collect data from subjects globally that can pass regulatory
review [7,13].
Decomissioning
What it is. Decomisssioning is the process for the system
provider to retire or decommission a system for both data and
services when a clinical trial ends. The decommissioning process
ensures that all open items are dispositioned and closed. This is
the ﬁnal step in the validation process. It is composed of the
following steps:1. Data completion: assurance that all patient data that have been
collected are uploaded from the patient devices to the ePRO
provider’s central database. This is followed by disabling
further data upload and locking of the database for download
in coordination with study team needs.2. Device returns (PDA-speciﬁc): accounting of the returned devi-
ces as well as cleaning (both SW and surface), recycling for
additional trials, or disposal.3. Documentation: assurance that the inventory of all required
validation documents and records exists in the vendor archive
repository.4. Notiﬁcations: notifying all internal and external support parties
and canceling services that are no longer necessary.
Why it is important. Decommissioning ensures that the devices,
systems, and services set up for a trial are no longer in use, that
all collected data have been transmitted to the study team, and
that only ofﬁcial copies remain.
Clinical trial team involvement. The team should be cognizant
of the ePRO provider’s decommissioning processes. This conﬁrms
privacy and conﬁdentiality and avoids unintended or erroneous
data collection. Figure. 1
Important quality management processes to be aware of. The
ePRO provider’s decommissioning team should be using a care-
fully developed quality-controlled checklist that provides docu-
mentation for the process on each device, internal quality
reviews of the process, and accountability for the staff executing
these processes [7,13].
Fig. 1 – Sample of traceability matrix.
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Validation of electronic systems to collect PRO data is a critical
component for a clinical trial’s regulatory approval. This report
addresses the technical nature of the ePRO data collection
systems and validation process, as well as how the process is
shared by the trial sponsor and the ePRO system provider. As a
result, the report should enhance the understanding of clinical
trial sponsors of the requirements for a technology review to
provide a basis for comparison of different ePRO system pro-
viders and their respective service offerings.Acknowledgments
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